218. アルポート症候群
[臨床試験数:16,薬物数:24(DrugBank:11),標的遺伝子数:5,標的パスウェイ数:27

Searched query = "Alport syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04573920
(ClinicalTrials.gov)
February 1, 202128/9/2020Atrasentan in Patients With Proteinuric Glomerular DiseasesA Phase 2, Open-Label, Basket Study of Atrasentan in Patients With Proteinuric Glomerular DiseasesIgA Nephropathy;Focal Segmental Glomerulosclerosis;Alport Syndrome;Diabetic Kidney Disease;Diabetic Nephropathy Type 2;Immunoglobulin A NephropathyDrug: AtrasentanChinook Therapeutics U.S., Inc.NULLNot yet recruiting18 YearsN/AAll80Phase 2NULL
2ChiCTR2000036799
2020-10-012020-08-25Construction and clinical transformation of integrated platform for accurate diagnosis and treatment of Alport syndromeConstruction and clinical transformation of integrated platform for accurate diagnosis and treatment of Alport syndrome Alport Syndromeexperimental group:Hydroxychloroquine + Benazepril Hydrochloridec;control group:placebo + benazepril hydrochloride;Shanghai Children's HospitalNULLPending018Bothexperimental group:25;control group:25;N/AChina
3ChiCTR2000036550
2020-09-012020-08-24Enzyme-linked immunosorbent determination of urine IV collagen alpha chain early warning value for Alport syndromeEnzyme-linked immunosorbent determination of urine IV collagen alpha chain early warning value for Alport syndrome Alport syndromeGold Standard:Renal biopsy, skin biopsy and genetic test.;Index test:urine IV collagen a chain test;Children's Hospital of ShanghaiNULLRecruiting018BothTarget condition:60;Difficult condition:70China
4NCT02855268
(ClinicalTrials.gov)
November 2, 201928/7/2016Study of SAR339375 in Patients With Alport SyndromeA Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Efficacy, Pharmacodynamics, and Pharmacokinetics of SAR339375 for Subcutaneous Injection Administered Every Week in Patients With Alport SyndromeAlport's SyndromeDrug: Lademirsen (SAR339375);Drug: PlaceboGenzyme, a Sanofi CompanyNULLRecruiting18 Years55 YearsAll45Phase 2United States;Australia;China;France;Germany;Spain;United Kingdom
5NCT03749447
(ClinicalTrials.gov)
March 8, 201919/11/2018An Extended Access Program for Bardoxolone Methyl in Patients With CKD (EAGLE)An Extended Access Program to Assess Long Term Safety of Bardoxolone Methyl in Patients With Chronic Kidney DiseaseChronic Kidney Diseases;Alport Syndrome;Autosomal Dominant Polycystic KidneyDrug: Bardoxolone methylReata Pharmaceuticals, Inc.NULLRecruiting12 YearsN/AAll480Phase 3United States;Australia;Japan;Puerto Rico
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6JPRN-UMIN000032448
2018/05/0101/05/2018A Phase 2/3 Trial of the Efficacy and Safety of Bardoxolone Methyl in Patients with Alport SyndromeA Phase 2/3 Trial of the Efficacy and Safety of Bardoxolone Methyl in Patients with Alport Syndrome - CARDINAL Alport SyndromeDrug: Bardoxolone Methyl
Bardoxolone methyl dose escalated from 5 mg to a maximum of 20 or 30 mg, depending on baseline proteinuria status. Dosing period is up to 2 years.
Drug: Placebo Oral Capsule
Capsule containing an inert placebo is administrated up to 2 years.
Reata Pharmaceuticals, IncNULLComplete: follow-up continuing12years-old70years-oldMale and Female180Phase 2;Phase 3Japan,North America,Australia,Europe
7EUCTR2016-004395-22-GB
(EUCTR)
28/03/201831/10/2017clinical study to evaluate the efficacy and safety of a new drug (Bardoxolone methyl) in the treatment of subjects with Alport syndromeA Phase 2/3 Trial of the Efficacy and Safety of Bardoxolone Methyl in Patients with Alport Syndrome - CARDINAL Alport Syndrome
MedDRA version: 20.0;Level: PT;Classification code 10001843;Term: Alport's syndrome;System Organ Class: 10010331 - Congenital, familial and genetic disorders ;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
Reata Pharmaceuticals, Inc.NULLAuthorised-recruitment may be ongoing or finished Female: yes
Male: yes
180Phase 2;Phase 3France;United States;Canada;Spain;Australia;Germany;United Kingdom
8NCT03373786
(ClinicalTrials.gov)
December 22, 201722/10/2017A Study of RG-012 in Subjects With Alport SyndromeA Phase 1, Open-Label Study to Evaluate the Safety, Pharmacodynamics, and Pharmacokinetics of RG-012 for Injection, Including Its Effect on Renal microRNA-21, in Subjects With Alport SyndromeAlport SyndromeDrug: RG012Genzyme, a Sanofi CompanyNULLCompleted18 Years65 YearsAll4Phase 1United States
9EUCTR2016-004395-22-DE
(EUCTR)
19/12/201725/09/2017clinical study to evaluate the efficacy and safety of a new drug (Bardoxolone methyl) in the treatment of subjects with Alport syndromeA Phase 2/3 Trial of the Efficacy and Safety of Bardoxolone Methyl in Patients with Alport Syndrome - CARDINAL Alport Syndrome
MedDRA version: 20.0;Level: PT;Classification code 10001843;Term: Alport's syndrome;System Organ Class: 10010331 - Congenital, familial and genetic disorders ;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
Reata Pharmaceuticals, Inc.NULLAuthorised-recruitment may be ongoing or finished Female: yes
Male: yes
180Phase 2;Phase 3France;United States;Canada;Spain;Australia;Germany;United Kingdom
10EUCTR2016-004395-22-FR
(EUCTR)
04/12/201705/12/2017clinical study to evaluate the efficacy and safety of a new drug (Bardoxolone methyl) in the treatment of subjects with Alport syndromeA Phase 2/3 Trial of the Efficacy and Safety of Bardoxolone Methyl in Patients with Alport Syndrome - CARDINAL Alport Syndrome
MedDRA version: 20.0;Level: PT;Classification code 10001843;Term: Alport's syndrome;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
Product Name: Bardoxolone Methyl
Product Code: RTA 402
INN or Proposed INN: bardoxolone methyl
Other descriptive name: BARDOXOLONE METHYL
Reata Pharmaceuticals, Inc.NULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
150Phase 2;Phase 3United States;France;Canada;Spain;Australia;Germany;United Kingdom
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
11NCT03019185
(ClinicalTrials.gov)
March 2, 20176/1/2017A Phase 2/3 Trial of the Efficacy and Safety of Bardoxolone Methyl in Patients With Alport Syndrome - CARDINALA Phase 2/3 Trial of the Efficacy and Safety of Bardoxolone Methyl in Patients With Alport SyndromeAlport SyndromeDrug: Placebo Oral Capsule;Drug: Bardoxolone MethylReata Pharmaceuticals, Inc.NULLCompleted12 Years60 YearsAll187Phase 2;Phase 3United States;Australia;France;Germany;Japan;Puerto Rico;Spain;United Kingdom;Canada
12EUCTR2016-002181-32-GB
(EUCTR)
07/12/201608/09/2016A research study to evaluate the safety and effectiveness of RG-012 as a treatment for patients with Alport syndromeA Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Pharmacodynamics, Pharmacokinetics, Dose Selection, and Preliminary Efficacy of Weekly RG 012 Injections in Patients with Alport Syndrome - A Phase 2 Study to Evaluate Weekly RG012 Injections in Alport Syndrome Alport syndrome is an inherited form of kidney disease caused by mutations in genes coding for the capillary basement membrane collagen IV;Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]Regulus Therapeutics Inc.NULLNot Recruiting Female: yes
Male: yes
30Phase 2France;United States;Canada;Spain;Australia;Germany;United Kingdom
13NCT01485978
(ClinicalTrials.gov)
March 20122/12/2011Efficacy and Safety Study to Delay Renal Failure in Children With Alport SyndromeEarly Prospective Therapy Trial to Delay Renal Failure in Children With Alport SyndromeRenal Insufficiency, ChronicDrug: Ramipril;Drug: placebo to ramiprilInstitut fuer anwendungsorientierte Forschung und klinische Studien GmbHUniversity Medical Center Goettingen;German Federal Ministry of Education and ResearchCompleted24 Months18 YearsAll66Phase 3Germany
14EUCTR2010-024300-10-DE
(EUCTR)
27/02/201212/12/2011Early prospective therapy trial to delay renal failure in children with Alport syndrome. - EARLY PRO-TECT AlportEarly prospective therapy trial to delay renal failure in children with Alport syndrome. - EARLY PRO-TECT Alport Alport's syndrome
MedDRA version: 19.1;Level: PT;Classification code 10001843;Term: Alport's syndrome;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
Trade Name: Delix
Product Name: Delix
Other descriptive name: RAMIPRIL
University Medical Center GöttingenNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
Phase 3Germany
15NCT00309257
(ClinicalTrials.gov)
January 200430/3/2006Effects of an Intensified Treatment With ACE-I,ATA II and Statins in Alport SyndromeEffects of an Intensified Treatment With ACE-inhibitors, Angiotensin II Receptor Antagonists and Statins in Alport SyndromeAlport SyndromeDrug: ACE I, ATA II and Statins;Drug: Benazepril, Valsartan and FluvastatinMario Negri Institute for Pharmacological ResearchNULLCompleted15 Years70 YearsBoth9Phase 2Italy
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
16NCT02378805
(ClinicalTrials.gov)
July 199526/2/2015European Alport Therapy Registry - European Initiative Towards Delaying Renal Failure in Alport SyndromeEuropean Alport Therapy Registry - European Initiative Towards Delaying Renal Failure in Alport Syndrome: Current and Novel TherapiesAlport Syndrome;Hereditary Kidney Disease;Pediatric Kidney Disease;Thin Basement Membrane Disease;Familial Benign HematuriaDrug: ACE-inhibitor;Drug: AT1-inhibitor;Drug: HMG-Coenzyme inhibitor (statin);Drug: Spironolactone;Drug: ParicalcitolUniversity Hospital GoettingenSociety for Pediatric Nephrology (Germany);Deutsche Gesellschaft für Nephrologie;Alport Selbsthilfe e.V.;Association pour l'Information et la Recherche sur les Maladies Rénales Génétiques (AIRG);KfH Foundation Preventive MedicineRecruitingN/AN/AAll500Germany